MIRM Quote, Financials, Valuation and Earnings

Cytokinetics has a net margin of -15.75% compared to Mirum Pharmaceuticals's net margin of -34674.95%. Mirum Pharmaceuticals's return on equity of -41.13% beat Cytokinetics's return on equity of --.

Mirum Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 49.4%. On the other hand Cytokinetics has an analysts' consensus of $81.71 which suggests that it could grow by 68.36%. Given that Cytokinetics has higher upside potential than Mirum Pharmaceuticals, analysts believe Cytokinetics is more attractive than Mirum Pharmaceuticals.

Mirum Pharmaceuticals has a beta of 1.200, which suggesting that the stock is 19.974% more volatile than S&P 500. In comparison Cytokinetics has a beta of 0.796, suggesting its less volatile than the S&P 500 by 20.368%.

Mirum Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

Mirum Pharmaceuticals quarterly revenues are $90.4M, which are larger than Cytokinetics quarterly revenues of $463K. Mirum Pharmaceuticals's net income of -$14.2M is higher than Cytokinetics's net income of -$160.5M. Notably, Mirum Pharmaceuticals's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals is 6.47x versus 1,612.94x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics has a net margin of -15.75% compared to Mirum Pharmaceuticals's net margin of -4.76%. Mirum Pharmaceuticals's return on equity of -41.13% beat Amicus Therapeutics's return on equity of -71.17%.

Mirum Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 49.4%. On the other hand Amicus Therapeutics has an analysts' consensus of -- which suggests that it could grow by 77.05%. Given that Amicus Therapeutics has higher upside potential than Mirum Pharmaceuticals, analysts believe Amicus Therapeutics is more attractive than Mirum Pharmaceuticals.

Mirum Pharmaceuticals has a beta of 1.200, which suggesting that the stock is 19.974% more volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.599, suggesting its less volatile than the S&P 500 by 40.114%.

Mirum Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Mirum Pharmaceuticals quarterly revenues are $90.4M, which are smaller than Amicus Therapeutics quarterly revenues of $141.5M. Mirum Pharmaceuticals's net income of -$14.2M is lower than Amicus Therapeutics's net income of -$6.7M. Notably, Mirum Pharmaceuticals's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals is 6.47x versus 6.01x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen has a net margin of -15.75% compared to Mirum Pharmaceuticals's net margin of -1141.73%. Mirum Pharmaceuticals's return on equity of -41.13% beat Ocugen's return on equity of -136.91%.

Mirum Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 49.4%. On the other hand Ocugen has an analysts' consensus of -- which suggests that it could grow by 770.23%. Given that Ocugen has higher upside potential than Mirum Pharmaceuticals, analysts believe Ocugen is more attractive than Mirum Pharmaceuticals.

Mirum Pharmaceuticals has a beta of 1.200, which suggesting that the stock is 19.974% more volatile than S&P 500. In comparison Ocugen has a beta of 3.823, suggesting its more volatile than the S&P 500 by 282.261%.

Mirum Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

Mirum Pharmaceuticals quarterly revenues are $90.4M, which are larger than Ocugen quarterly revenues of $1.1M. Mirum Pharmaceuticals's net income of -$14.2M is lower than Ocugen's net income of -$13M. Notably, Mirum Pharmaceuticals's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals is 6.47x versus 40.09x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

Scholar Rock Holding has a net margin of -15.75% compared to Mirum Pharmaceuticals's net margin of --. Mirum Pharmaceuticals's return on equity of -41.13% beat Scholar Rock Holding's return on equity of --.

Mirum Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 49.4%. On the other hand Scholar Rock Holding has an analysts' consensus of $46.38 which suggests that it could grow by 1.79%. Given that Mirum Pharmaceuticals has higher upside potential than Scholar Rock Holding, analysts believe Mirum Pharmaceuticals is more attractive than Scholar Rock Holding.

Mirum Pharmaceuticals has a beta of 1.200, which suggesting that the stock is 19.974% more volatile than S&P 500. In comparison Scholar Rock Holding has a beta of 0.578, suggesting its less volatile than the S&P 500 by 42.249%.

Mirum Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scholar Rock Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals pays -- of its earnings as a dividend. Scholar Rock Holding pays out -- of its earnings as a dividend.

Mirum Pharmaceuticals quarterly revenues are $90.4M, which are larger than Scholar Rock Holding quarterly revenues of --. Mirum Pharmaceuticals's net income of -$14.2M is higher than Scholar Rock Holding's net income of -$64.5M. Notably, Mirum Pharmaceuticals's price-to-earnings ratio is -- while Scholar Rock Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals is 6.47x versus 92.18x for Scholar Rock Holding. Usually stocks with elevated PS ratios are considered overvalued.